A detailed history of Aviance Capital Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Aviance Capital Partners, LLC holds 143,096 shares of ABBV stock, worth $25.8 Million. This represents 3.86% of its overall portfolio holdings.

Number of Shares
143,096
Previous 142,647 0.31%
Holding current value
$25.8 Million
Previous $24.5 Million 15.5%
% of portfolio
3.86%
Previous 3.59%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$163.84 - $199.33 $73,564 - $89,499
449 Added 0.31%
143,096 $28.3 Million
Q2 2024

Aug 09, 2024

BUY
$154.79 - $180.76 $155,718 - $181,844
1,006 Added 0.71%
142,647 $24.5 Million
Q1 2024

Apr 17, 2024

BUY
$159.82 - $182.1 $3.04 Million - $3.46 Million
19,028 Added 15.52%
141,641 $25.8 Million
Q4 2023

Feb 06, 2024

SELL
$137.6 - $154.97 $372,070 - $419,038
-2,704 Reduced 2.16%
122,613 $19 Million
Q3 2023

Nov 06, 2023

SELL
$133.59 - $154.65 $487,069 - $563,853
-3,646 Reduced 2.83%
125,317 $18.7 Million
Q2 2023

Aug 04, 2023

SELL
$132.51 - $164.9 $4.13 Million - $5.14 Million
-31,196 Reduced 19.48%
128,963 $17.4 Million
Q1 2023

May 10, 2023

SELL
$144.61 - $166.54 $1.75 Million - $2.02 Million
-12,133 Reduced 7.04%
160,159 $25.5 Million
Q4 2022

Feb 06, 2023

SELL
$138.31 - $165.87 $174,823 - $209,659
-1,264 Reduced 0.73%
172,292 $27.9 Million
Q3 2022

Nov 09, 2022

SELL
$134.21 - $153.93 $9,126 - $10,467
-68 Reduced 0.04%
173,556 $23.3 Million
Q2 2022

Aug 08, 2022

BUY
$137.62 - $174.96 $1.95 Million - $2.48 Million
14,164 Added 8.88%
173,624 $26.6 Million
Q1 2022

May 06, 2022

BUY
$131.98 - $163.75 $255,777 - $317,347
1,938 Added 1.23%
159,460 $25.9 Million
Q4 2021

Feb 07, 2022

BUY
$107.43 - $135.93 $124,189 - $157,135
1,156 Added 0.74%
157,522 $21.3 Million
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $470,181 - $533,726
4,419 Added 2.91%
156,366 $16.9 Million
Q2 2021

Aug 06, 2021

BUY
$105.21 - $117.21 $399,377 - $444,929
3,796 Added 2.56%
151,947 $17.1 Million
Q1 2021

Apr 29, 2021

BUY
$102.3 - $112.62 $22,710 - $25,001
222 Added 0.15%
148,151 $16 Million
Q4 2020

Feb 12, 2021

BUY
$80.49 - $108.67 $54,652 - $73,786
679 Added 0.46%
147,929 $15.9 Million
Q3 2020

Nov 03, 2020

BUY
$85.91 - $100.83 $155,583 - $182,603
1,811 Added 1.25%
147,250 $12.9 Million
Q2 2020

Jul 24, 2020

BUY
$73.37 - $98.18 $8.98 Million - $12 Million
122,360 Added 530.18%
145,439 $14.3 Million
Q1 2020

May 05, 2020

SELL
$64.5 - $97.79 $1.46 Million - $2.22 Million
-22,703 Reduced 49.59%
23,079 $1.76 Million
Q4 2019

Feb 07, 2020

BUY
$72.13 - $90.25 $107,762 - $134,833
1,494 Added 3.37%
45,782 $4.05 Million
Q3 2019

Nov 07, 2019

BUY
$62.98 - $75.72 $616,574 - $741,298
9,790 Added 28.38%
44,288 $3.35 Million
Q2 2019

Aug 12, 2019

SELL
$65.7 - $83.98 $18,724 - $23,934
-285 Reduced 0.82%
34,498 $2.51 Million
Q1 2019

May 01, 2019

SELL
$77.14 - $90.79 $421,184 - $495,713
-5,460 Reduced 13.57%
34,783 $2.8 Million
Q4 2018

Feb 11, 2019

SELL
$77.85 - $96.01 $170,102 - $209,781
-2,185 Reduced 5.15%
40,243 $3.71 Million
Q3 2018

Nov 09, 2018

SELL
$88.91 - $98.84 $50,323 - $55,943
-566 Reduced 1.32%
42,428 $4.01 Million
Q2 2018

Aug 10, 2018

BUY
$89.78 - $106.23 $4,848 - $5,736
54 Added 0.13%
42,994 $3.98 Million
Q1 2018

May 03, 2018

BUY
$92.01 - $123.21 $204,446 - $273,772
2,222 Added 5.46%
42,940 $4.06 Million
Q4 2017

Feb 13, 2018

BUY
$89.56 - $98.21 $12,986 - $14,240
145 Added 0.36%
40,718 $3.94 Million
Q3 2017

Nov 09, 2017

BUY
$69.85 - $89.22 $2.83 Million - $3.62 Million
40,573
40,573 $3.61 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Aviance Capital Partners, LLC Portfolio

Follow Aviance Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviance Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviance Capital Partners, LLC with notifications on news.